1. Home
  2. CYBN vs ECF Comparison

CYBN vs ECF Comparison

Compare CYBN & ECF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYBN
  • ECF
  • Stock Information
  • Founded
  • CYBN 2019
  • ECF 1986
  • Country
  • CYBN Canada
  • ECF United States
  • Employees
  • CYBN N/A
  • ECF N/A
  • Industry
  • CYBN Pharmaceuticals and Biotechnology
  • ECF Finance/Investors Services
  • Sector
  • CYBN Health Care
  • ECF Finance
  • Exchange
  • CYBN Nasdaq
  • ECF Nasdaq
  • Market Cap
  • CYBN 176.5M
  • ECF 150.0M
  • IPO Year
  • CYBN N/A
  • ECF N/A
  • Fundamental
  • Price
  • CYBN $6.07
  • ECF $11.74
  • Analyst Decision
  • CYBN Strong Buy
  • ECF
  • Analyst Count
  • CYBN 3
  • ECF 0
  • Target Price
  • CYBN $85.00
  • ECF N/A
  • AVG Volume (30 Days)
  • CYBN 673.9K
  • ECF 57.7K
  • Earning Date
  • CYBN 11-12-2025
  • ECF 01-01-0001
  • Dividend Yield
  • CYBN N/A
  • ECF 6.42%
  • EPS Growth
  • CYBN N/A
  • ECF N/A
  • EPS
  • CYBN N/A
  • ECF 0.46
  • Revenue
  • CYBN N/A
  • ECF N/A
  • Revenue This Year
  • CYBN N/A
  • ECF N/A
  • Revenue Next Year
  • CYBN N/A
  • ECF N/A
  • P/E Ratio
  • CYBN N/A
  • ECF $17.61
  • Revenue Growth
  • CYBN N/A
  • ECF N/A
  • 52 Week Low
  • CYBN $4.81
  • ECF $7.02
  • 52 Week High
  • CYBN $13.88
  • ECF $8.91
  • Technical
  • Relative Strength Index (RSI)
  • CYBN 45.10
  • ECF 64.56
  • Support Level
  • CYBN $5.72
  • ECF $11.39
  • Resistance Level
  • CYBN $6.52
  • ECF $11.90
  • Average True Range (ATR)
  • CYBN 0.30
  • ECF 0.17
  • MACD
  • CYBN 0.05
  • ECF -0.02
  • Stochastic Oscillator
  • CYBN 38.48
  • ECF 70.00

About CYBN Cybin Inc.

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

About ECF Ellsworth Growth and Income Fund Ltd.

Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.

Share on Social Networks: